Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT04363684 · View on ClinicalTrials.gov ↗

Study Summary

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

Study Locations (20)

California

  • University of California, Los Angeles — Los Angeles
  • University of California, San Diego — San Diego
  • University of California San Francisco — San Francisco

Maryland

  • Johns Hopkins University — Baltimore
  • NIH — Bethesda

New York

  • Mount Sinai — New York
  • Columbia University — New York

Alabama

  • University of Alabama Birmingham — Birmingham

Colorado

  • University of Colorado Denver — Denver

Florida

  • Mayo Clinic Florida — Jacksonville

Georgia

  • Emory University — Atlanta

Illinois

  • Northwestern University — Chicago

Trial Details

FieldValue
Enrollment Target 2,100 participants
Start Date 2020-03-01
Est. Completion 2026-06-30

Sponsor

Mayo Clinic

3,246 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04363684

The ClinicalTrials.gov registry entry for NCT04363684 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 3,246 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 10 conditions, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04363684 reports 20 study locations spanning 16 distinct geographic areas — top geographies include California, Maryland, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04363684 about?

NCT04363684 is a clinical study titled "ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)". ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

What is the current status of trial NCT04363684?

This trial is currently recruiting. The enrollment target is 2,100 participants. The study started on 2020-03-01. Estimated completion is 2026-06-30.

What conditions does trial NCT04363684 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Semantic Variant Primary Progressive Aphasia (svPPA). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT04363684?

This trial is sponsored by Mayo Clinic, which has 3,246 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04363684 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial